Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.

The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV infection. Early predictors of these CoRs could provide insight into vacc...

Full description

Bibliographic Details
Main Authors:	Erica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, Lindsay N Carpp, Anneta F Naidoo, Michael S Harper, Valentin Voillet, Nicole Grunenberg, Fatima Laher, Craig Innes, Linda-Gail Bekker, James G Kublin, Ying Huang, Guido Ferrari, Georgia D Tomaras, Glenda Gray, Peter B Gilbert, M Juliana McElrath
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2021-03-01
Series:	PLoS Pathogens
Online Access:	https://doi.org/10.1371/journal.ppat.1009363

Similar Items

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial.
by: Rephaim Mpofu, et al.
Published: (2021-01-01)

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.
by: Jacob A Cram, et al.
Published: (2019-01-01)

Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines
by: Koshlan Mayer-Blackwell, et al.
Published: (2022-10-01)

HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.
by: Kelly E Seaton, et al.
Published: (2014-01-01)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.
by: Kathryn L Hopkins, et al.
Published: (2014-01-01)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
by: Zoe Moodie, et al.
Published: (2020-05-01)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
by: Fatima Laher, et al.
Published: (2020-02-01)

Hope for HIV control in southern Africa: The continued quest for a vaccine.
by: Linda-Gail Bekker, et al.
Published: (2017-02-01)

Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa.
by: Erica Maxine Lazarus, et al.
Published: (2014-01-01)

Attracting, equipping and retaining young medical doctors in HIV vaccine science in South Africa
by: Danna Flood, et al.
Published: (2015-11-01)

HIV counselling
by: Linda-Gail Bekker
Published: (2002-07-01)

Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells
by: Leigh Fisher, et al.
Published: (2019-11-01)

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
by: Lue Ping Zhao, et al.
Published: (2020-01-01)

Real-time polymerase chain reaction optimised for hepatitis C virus detection in dried blood spots from HIV-exposed infants, KwaZulu-Natal, South Africa
by: Anneta Naidoo, et al.
Published: (2016-03-01)

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
by: Zoe Moodie, et al.
Published: (2024-03-01)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
by: Zanele Ditse, et al.
Published: (2020-02-01)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
by: McElrath J, et al.
Published: (2009-10-01)

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
by: Yunda Huang, et al.
Published: (2022-10-01)

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.
by: Samuel O Pine, et al.
Published: (2011-04-01)

Vaginal practices among women at risk for HIV acquisition in Soweto, South Africa
by: Erica Lazarus, et al.
Published: (2019-06-01)

Bringing the path toward an HIV-1 vaccine into focus.
by: Cesar J Lopez Angel, et al.
Published: (2020-09-01)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants.
by: Nicole Espy, et al.
Published: (2023-01-01)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
by: Nicole Espy, et al.
Published: (2023-01-01)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.
by: Susan P Buchbinder, et al.
Published: (2017-01-01)

A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa
by: Linda-Gail Bekker, et al.
Published: (2020-04-01)

Dynamics of viral evolution and CTL responses in HIV-1 infection.
by: Yi Liu, et al.
Published: (2011-01-01)

Can we involve adolescents in HIV vaccine trials - can we afford not to?
by: Linda-Gail Bekker
Published: (2005-05-01)

Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates
by: Georgia D. Tomaras, et al.
Published: (2013-12-01)

Cell free HIV-1 virus can infect inner and outer foreskin polarized explants
by: Lemos MP, et al.
Published: (2012-09-01)

Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans
by: Shiwei Xu, et al.
Published: (2022-08-01)

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).
by: Laurence Peiperl, et al.
Published: (2010-10-01)

The power of peers and community in the continuum of HIV care
by: Anna T Grimsrud, et al.
Published: (2020-02-01)

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.
by: Andrew Fiore-Gartland, et al.
Published: (2016-01-01)

Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transcriptional programs
by: Andersen-Nissen E, et al.
Published: (2012-09-01)

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
by: Gavin J Churchyard, et al.
Published: (2011-01-01)

Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trialResearch in context
by: Maurine D. Miner, et al.
Published: (2024-02-01)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.
by: Gavin Churchyard, et al.
Published: (2016-01-01)

Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency
by: Germán Gustavo Gornalusse, et al.
Published: (2021-07-01)

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
by: Kelly E. Seaton, et al.
Published: (2021-04-01)

ICT & HIV prevention: Experiences from a biomedical HIV prevention trial among men who have sex with men (MSM) in Cape Town, South Africa
by: Andrew Scheibe, Ben Brown and Linda-Gail Bekker
Published: (2012-04-01)